Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

Company: BioLineRx Ltd. Date: 2025-05-30 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.htm) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

   

New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meetin false

|     |     |
| --- | --- |
| ������� �� ��� ��"� | 2 380 |
| BIOLINE RX LTD |
| Corporation no: 513398750 | 8688 |
| - - - |
|     |

|     |     |     |     |     |     |     |     |     |     |     |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|     | Israel Securities Authority |     |     | Tel Aviv Stock Exchange |     | C002 ( Public ) |     | Reported via MAGNA: | 30/05/2025 |     |
|     | www.isa.gov.il |     |     | www.tase.co.il |     |     |     | Reference: | 2025-02-039497 | Time of broadcast: 15:15 15:15 |

- - -

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000  

  

|     |     |
| --- | --- |
|     | The corporation is a foreign private issuer as defined by U.S. Securities Laws. |

  

Attached hereto is a report on*New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting*  

*6-K\_30-May-25\_isa.pdf*

|     |     |
| --- | --- |
|     |     |
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): |     |
|     |     |
|     |     |
| - - - |     |
| Stock Exchange/Market: NASDAQ CM | Date of revision of form structure: 06/08/2024 |
| Address: HaMa'ayan 2 , Modi'in 7177871   , Israel Tel: 08-6429100 , Fax: 08-6429101 |     |
| E-mail address: info@BioLineRx.com   Company site: www.biolinerx.com |     |
|     |     |
| Previous names of reporting entity: |     |
|     |     |
| Name of the Signatory: Serlin Philip Adam Position of Signatory in the reporting corporation: Chief Executive Officer Name of Employer Company: |     |
| Address: HaMa'ayan 2 , Modi'in 7177871 Telephone: 08-6429100 Facsimile: 08-6429101 E-mail: phils@biolinerx.com 1 |     |
| Israel |